

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Wed May 16 10:17:01 EDT 2007

=====

Application No: 10657567

Version No: 1.0

Input Set:

Output Set:

Started: 2007-05-14 17:29:34.719

Finished: 2007-05-14 17:29:35.288

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 569 ms

Total Warnings: 9

Total Errors: 0

No. of SeqIDs Defined: 9

Actual SeqID Count: 9

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)

# SEQUENCE LISTING

<110> Fobian, Yvette M  
Freskos, John N  
Jagodzinska, Barbara

<120> 1,3-Diamino-2-Hydroxypropane Pro-Drug Derivatives

<130> 02-760-A

<140> 10657567

<141> 2007-05-14

<150> 10/657,567

<151> 2003-09-08

<150> 60/408,783

<151> 2002-09-06

<160> 9

<170> PatentIn version 3.4

<210> 1

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<220>

<221> MISC\_FEATURE

<222> (11)..(11)

<223> covalent attachment of oregon green

<400> 1

Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys Lys Lys

1

5

10

<210> 2

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal biotin

<220>  
<221> MISC\_FEATURE  
<222> (11)..(11)  
<223> covalent attachment of oregon green

<400> 2

Ser Glu Val Lys Met Asp Ala Glu Phe Arg Cys Lys Lys  
1 5 10

<210> 3  
<211> 22  
<212> PRT  
<213> Artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal biotin

<220>  
<221> MISC\_FEATURE  
<222> (20)..(20)  
<223> covalent attachment of oregon green

<400> 3

Gly Leu Asn Ile Lys Thr Glu Glu Ile Ser Glu Ile Ser Tyr Glu Val  
1 5 10 15

Glu Phe Arg Cys Lys Lys  
20

<210> 4  
<211> 34  
<212> PRT  
<213> Artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)

<223> N-terminal biotin

<220>

<221> MISC\_FEATURE

<222> (32)..(32)

<223> covalent attachment of oregon green

<400> 4

Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile  
1 5 10 15

Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe Arg Cys  
20 25 30

Lys Lys

<210> 5

<211> 33

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic peptide

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> N-terminal biotin

<220>

<221> MISC\_FEATURE

<222> (7)..(7)

<223> oxidized cysteine

<220>

<221> MISC\_FEATURE

<222> (19)..(19)

<223> oxidized cysteine

<220>

<221> MISC\_FEATURE

<222> (31)..(31)

<223> covalent attachment of oregon green

<400> 5

Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr  
1 5 10 15

Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala Cys Lys

Lys

<210> 6  
<211> 33  
<212> PRT  
<213> Artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal biotin

<400> 6

Cys	Gly	Gly	Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly	Ser	Gly	Leu
1				5				10					15		

Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Asn	Leu	Asp	Ala	Glu
			20					25					30		

Phe

<210> 7  
<211> 29  
<212> PRT  
<213> Artificial sequence

<220>  
<223> synthetic peptide

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> N-terminal biotin

<400> 7

Cys	Gly	Gly	Ala	Asp	Arg	Gly	Leu	Thr	Thr	Arg	Pro	Gly	Ser	Gly	Leu
1				5				10					15		

Thr	Asn	Ile	Lys	Thr	Glu	Glu	Ile	Ser	Glu	Val	Asn	Leu
			20					25				

<210> 8  
<211> 9  
<212> PRT  
<213> Artificial sequence

<220>  
<223> synthetic peptide

<400> 8

Ser Glu Val Asn Leu Asp Ala Glu Phe  
1 5

<210> 9  
<211> 30  
<212> PRT  
<213> Artificial sequence

<220>  
<223> synthetic peptide

<400> 9

Ala Asp Arg Gly Leu Thr Thr Arg Pro Gly Ser Gly Leu Thr Asn Ile  
1 5 10 15

Lys Thr Glu Glu Ile Ser Glu Val Asn Leu Asp Ala Glu Phe  
20 25 30